North American Vaccine, Pasteur Merieux-Connaught deal

NVX signed a previously announced development and license agreement with Pasteur Merieux-Connaught under which the companies will co-develop NVX's conjugate vaccine against meningitis B for both adult and pediatric indications (see BioCentury Oct. 9, 1995).

NVX has received $3 million in development payments from Pasteur Merieux-Connaught. NVX would receive a first $10 million milestone upon completion of a preclinical study of the vaccine, and total fees to NVX could reach $52 million. ...